This stock will help you navigate the New Bull Market
In almost every single bull market, stock prices have risen as a result of new technological innovations. In the 1920s, it was the automobile. The 1980's were dominated by the personal computer, followed by the .COM bubble of the 1990's. In March, we witnessed an end to a ten-year bull market driven by FANG. A question many forward-thinking investors now ask themselves is what will drive this new bull market?
Ilumina (ILMN) is a biotech company that specializes in genome sequencing. This technology allows doctors to map a patient's genome, and identify hereditary diseases and mutations like cancer before they surface. While Illumina has been in business for 22 years, the amount of money one would have to pay when this technology was new was too steep to be used by mainstream medicine. However, Moore’s law has proven that the price and quality of services will only improve over time.
Created in 1965 by one of Intel's founders, Gordon Moore, Moore’s law states that the number of transistors in a computer would double every year. Thus far, this prediction has proved to be wildly accurate and serves as a benchmark goal for chip companies. In biotech, substantial computing power is needed by doctors to read an entire genome. In the last 20 years alone, Moore’s law has advanced at such a rate that the initial price of mapping a genome dropped from $100,000,000 to less than $1,000. Based on the law of supply and demand, the cheaper genome sequencing becomes, the demand for it will increase. As the innovation cycle in our new bull market advances, you can expect lower prices in genetic sequencing and radical changes to how modern medicine functions.
As genome sequencing becomes more accessible, insurance companies will protect their bottom line by covering this service during annual checkups. Naturally, this represents a net benefit to insurance companies, as they will be able to reduce risk and avoid shelling out large premiums to their customer's healthcare providers. Within the next ten years, genome mapping will become a mainstay in modern medicine and the world economy.
As of right now, Illumina has a sterling balance sheet with $36 billion in assets and $46 million in liabilities. As of their Q2 earnings announcement, their revenue is $1.49 billion. As a frame of reference, in 2019 ILMN’s total revenue was $1.685 billion.
Dr Nathaniel Heintz’s lab of Rockefeller University was credited for advancing ILMN’s genome test kit. The Rockefeller family, through its many trusts and entities, owns a large 9-figure position. They have made a fortune by investing in the pharmaceutical and biotech sectors. Over the past 4 years, the family has moved more and more of its investment fortune into biotech, sensing where the next big boom will come from as we approach a new frontier of scientific innovation during the next decade.
For less company-specific risk, yet still harvesting gains from this explosion in biotech and pharmaceuticals, one can look to ETF's such as XBI and IBB.
All opinions, information and illustrations expressed are solely for information and educational purposes and do not constitute investment or trading advice. We bear no responsibility for any actions taken or not taken by third parties after reading the blog. This email content has no regard to your own investment objectives, financial situation or particular needs. We may have an interest and may make purchases, sales or short sales in the securities referred to in the financial educational platform blog. Please ask for our consent before re-publishing blog content.
Investing in the financial markets can involve considerable risk, including loss of principal. Past performance is not necessarily an indication of future performance. Actual clients may achieve results materially different from the results portrayed. All material is for informational and educational purposes only and is not investment advice and is not meant to suggest that any securities are suitable investments for any particular investor. All information reflects our own actions, beliefs, and processes for purely informational purposes. Hedge Fund Z LLC is a financial blog for the sole purpose of information. HFZ does not represent themselves as acting in the position of an investment advisor or investment manager for funds that are not under their direct control and fiduciary responsibility. Third party quotes and information may not be representative of the experience of HFZ customers and do not represent a guarantee of future performance or success. Many of the results displayed on our website were achieved using leverage, such as 2x or 3x leveraged ETF's or equity options. The information included at HFZ and HFZ writing, research, and updates is prepared for educational purposes and is not a solicitation, or an offer to buy or sell any security or use any particular system. Information is based on historical research using data believed to be reliable, but there is no guarantee as to its accuracy. HFZ does not represent themselves as acting in the position of an investment adviser, bank or investment manager for funds that are not under their direct control and fiduciary responsibility. HFZ will not provide you with personally tailored advice concerning the nature, potential, value or suitability of any particular security, portfolio or securities, transaction, investment strategy or other matter. No information, nor any opinion expressed on the Site or in the Services, shall constitute a solicitation or an offer to buy or sell any securities mentioned therein. The information presented on the Site and in the Services has been prepared without regard to any particular investor's investment objectives, financial situation, needs, capacity, and trading ability or experience. Accordingly, you should not act on any information on the Site or in the Services without obtaining specific advice from your financial advisors and should not rely on information herein as the basis for your trading and/or investment decisions. HFZ cannot claim or represent that any of our Services are suitable for you. By your use of the Site and Services, you're agreeing that you bear responsibility for your own investment research, trades, and investment decisions. Only you can decide whether or not a trade is right for you and you agree to be liable for any trades you initiate at your brokerage using research and/or tools that we provide. If you ignore our advice to do independent research and choose instead to trade solely on information, analysis, alerts or opinions found in our Service or website, you have made a conscious, willing, free, and personal decision to do so. You also agree that HFZ, its directors, its employees, subsidiaries, affiliates, and its agents will not be liable for any investment decision, trade made or action taken by you and others based on news, information, opinion, or any other material published through our Site and Services.